Phase I trial of the anthrapyrazole CI-941: Prospective evaluation of a pharmacokinetically guided dose-escalation

This publication has 15 references indexed in Scilit:

• Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology
  Cancer Chemotherapy and Pharmacology, 1991
• Determination of the anthrapyrazole anticancer drug CI-941 in plasma and urine by solid-phase extraction and high-performance liquid chromatography
  Journal of Chromatography B: Biomedical Sciences and Applications, 1989
• The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients
  Cancer Chemotherapy and Pharmacology, 1989
• The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes
  Biochemical Pharmacology, 1987
• Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines
  European Journal of Cancer and Clinical Oncology, 1987
• Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias
  Journal of Medicinal Chemistry, 1987
• Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity
  Annals of Internal Medicine, 1986
• In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles)
  Biochemical Pharmacology, 1985
• Application of Stepwise Regression to Non-Linear Estimation
  Technometrics, 1968
• Predicting anticancer drug effects in man from laboratory animal studies
  Journal of Chronic Diseases, 1962